Clinical trial
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA)…
NCT07176390 · Merck Sharp & Dohme LLC, Industry · Recruiting
Key facts
| NCT number | NCT07176390 |
|---|---|
| Title | A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) |
| Official title | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | Tulisokibart, Placebo, Methotrexate |
| Enrollment | 182 |
| Start date | Oct 8, 2025 |
| Primary completion | Mar 8, 2027 |
| Completion | Sep 3, 2029 |
| First posted | Sep 16, 2025 |
| Last update posted | Feb 12, 2026 |
| Countries | Canada, China, Colombia, Germany, Japan, Poland, South Korea, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: